Common genetic markers and prediction of recurrent events after ischemic stroke in young adults

Neurology

Volumn 73, Issue 9, 2009, Pages 717-723

  Pezzini, A ^a   Grassi, M ^c   Del Zotto, E ^a,b   Lodigiani, C ^d   Ferrazzi, P ^d   Spalloni, A ^e   Patella, R ^e   Giossi, A ^a   Volonghi, I ^a   Iacoviello, L ^f   Magoni, M ^g   Rota, L L ^d   Rasura, M ^e   Padovani, A ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g SPEDALI CIVILI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5; PROTHROMBIN;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; BRAIN ISCHEMIA; DNA MUTATIONAL ANALYSIS; FACTOR V; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MASS SCREENING; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTHROMBIN; RECURRENCE; RISK FACTORS; STROKE; YOUNG ADULT;

EID: 70349339230     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181b59aaf     Document Type: Article

References (26)

1. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-years risk of recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke 2004;35:731-735.
2. van Wijk I, Kappelle LJ, van Gijn J, et al. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet 2005; 365:2098-2104.
3. Touzé E, Varenne O, Chatellier G, Peyrard S, Rothwell PM, Mas JL. Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and meta-analysis. Stroke 2005;36:2748-2755.
4. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Anderson CS. Long term disability after first-ever stroke and related prognostic factors in the Perth Community Stroke Study, 1989-1990. Stroke 2002;33:1034-1040.
5. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication- the Framingham Study. Stroke 1994;25:40-43.
6. Casas JP, Hingorani AD, Bautista LE, Sharma P. Metaanalysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18000 cases and 58000 controls. Arch Neurol 2004;61:1652-1662.
7. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003;146:948-957.
8. Pezzini A, Grassi M, Del Zotto E, et al. Cumulative effect of predisposing genotypes and their interaction with modifiable factors on the risk of ischemic stroke in young adults. Stroke 2005;36:533-539.
9. Johnson CJ, Kittner SJ, McCarter RJ, et al. Interrater reliability of an etiologic classification of ischemic stroke. Stroke 1995;26:46-51.
10. European Stroke Initiative: European Stroke Initiative recommendations for stroke management. European Stroke Council, European Neurological Society and European Federation of Neurological Societies. Cerebrovasc Dis 2000;10:335-351.
11. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia 2004;24(suppl 1):24-36.
12. Morris DL, Kritchevsky SB, Davis CE. Serum carotenoids and coronary heart disease: the Lipid Research Clinics Coronary Primary Prevention Trial and Follow-up study. JAMA 1994;272:1439-1441
13. Ripoll L, Paulin D, Drouet LO. Multiplex PCR-mediated site-directed mutagenesis for one-step determination of factor V Leiden and G20210A transition of the prothrombin gene. Thromb Haemost 1997;78:960-961.
14. Frosst P, Blom HJ, Milos R, Goyette P, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10: 111-113.
15. Harrel FE. Regression Modelling Strategies. New York: Springer; 2001.
16. Harrel FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982;247:2543-2546.
17. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007;115: 928-935.
18. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172.
19. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-641.
20. Haverkate F. Low-grade acute-phase reactions on arteriosclerosis and the consequences for hemostatic risk factors. Fibrinolysis 1992;6(suppl 3):17-18.
21. Feinberg WM, Erickson LP, Bruck D, Kittelson J. Hemostatic markers in acute ischemic stroke: association with stroke type, severity, and outcome. Stroke 1996;27:1296-1300.
22. Tohgi H, Konno S, Takahashi S, Koizumi D, Kondo R, Takahashi H. Activated coagulation/fibrinolysis system and platelet function in acute thrombotic stroke patients with increased C-reactive protein levels. Thromb Res 2000;100:373-379.
23. Naess H, Waje-Andreassen U, Thomassen L, Nyland H, Myhr KM. Do all young ischemic stroke patients need long-term secondary preventive medication? Neurology 2005;65:609-611.
24. Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA Project: C677T mutation in the methylenetetrahydrofolate reductase gene and risk of venous thromboembolism. Br J Haematol 1997;97:804-806.
25. Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA Project: prothrombin G20210A mutation and venous thromboembolism in the general population. Thromb Haemost 1999;82:1395-1398.
26. Tosetto A, Missiaglia E, Gatta E, Rodeghiero F. The VITA Project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Thromb Haemost 1997;78:859-863.